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Abstract
Purpose When postoperative ileus is not resolved after 5 days
or recurs after resolution, prolonged POI (PPOI) is diagnosed.
PPOI increases discomfort, morbidity and hospitalisation
length, and is mainly caused by an inflammatory response
following intestinal manipulation. This response can be weak-
ened by targeting the cholinergic anti-inflammatory pathway,
with nicotine as essential regulator. Chewing gum, already
known to stimulate gastrointestinal motility itself, combined
with nicotine is hypothesised to improve gastrointestinal re-
covery and prevent PPOI. This pilot study is the first to assess
efficacy and safety of nicotine gum in colorectal surgery.
Methods Patients undergoing elective oncological colorectal
surgery were enrolled in this double-blind, parallel-group,
controlled trial and randomly assigned to a treatment protocol
with normal or nicotine gum (2 mg). Patient reported out-
comes (PROMS), clinical characteristics and blood samples
were collected. Primary endpoint was defined as time to first
passage of faeces and toleration of solid food for at least 24 h.
Results In total, 40 patients were enrolled (20 vs. 20). In both
groups, six patients developed PPOI. Time to primary end-
point (4.50 [3.00–7.25] vs. 3.50 days [3.00–4.25],
p = 0.398) and length of stay (5.50 [4.00–8.50] vs. 4.50 days
[4.00–6.00], p = 0.738) did not differ significantly between
normal and nicotine gum. There were no differences in
PROMS, inflammatory parameters and postoperative
complications.
Conclusions We proved nicotine gum to be safe but ineffec-
tive in improving gastrointestinal recovery and prevention of
PPOI after colorectal surgery. Other dosages and administra-
tion routes of nicotine should be tested in future research.
Keywords Postoperative ileus . Prevention . Nicotine
chewing gum . Colorectal surgery
Introduction
Postoperative ileus (POI) is a temporary inhibition of gastro-
intestinal motility after abdominal surgery and is usually as-
sociated with nausea, vomiting, abdominal distension and
lack of flatus and defaecation [1, 2]. In more than 50% of
cases, POI is not fully resolved in 4 days after the operation
and when it does not resolve after 5 days or recurs after an
apparent resolution, prolonged POI (PPOI) is diagnosed [3, 4].
PPOI causes an increase in patient discomfort, morbidity,
hospital-acquired infections, hospitalisation days and
healthcare costs [5].
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The aetiology of POI is complex, with multiple factors
contributing to its pathogenesis [6]. Opioid use for postoper-
ative analgesia is known to inhibit gastrointestinal transit and
prolong POI [7, 8]. However, the development of POI after
abdominal surgery is mainly caused by intestinal manipula-
tion during the surgical procedure, thereby triggering an in-
flammatory response and causing a sustained and generalised
gastrointestinal hypomotility [7, 9, 10]. Targeting this inflam-
matory response is of clinical relevance, but effective strate-
gies are not yet available in clinical practice [8].
The cholinergic anti-inflammatory pathway (CAIP) is one
of the mechanisms that can be targeted for the prevention of
POI. Experimental studies have shown that mediation of
CAIP by vagus nerve stimulation can increase bowel motility
and control inflammatory cell recruitment, by that preventing
pathological changes important in the development of POI [1,
8, 11]. Moreover, nicotinic acetylcholine receptors (nAChR)
play an important role in mediation of CAIP, making nicotine
an essential regulator of the pathway [11–13]. Additionally,
the α7-nAChR also plays a role in nicotine-induced analgesia
[14] and clinical evidence shows that preoperative transdermal
and intranasal administration of nicotine significantly reduced
postoperative opioid use [15, 16], while reducing opioids is an
important strategy of shortening POI [1, 8, 17].
Gum chewing is another important strategy, which has al-
ready been proven to be beneficial for gastrointestinal recov-
ery after surgery. Several systematic reviews and meta-
analyses have been published, supporting postoperative gum
chewing in abdominal surgery [18–23]. As a form of sham
feeding, it mimics the cephalic phase of digestion and stimu-
lates the gastrointestinal motility via neurohormonal and vagal
pathways [18, 24]. Combining perioperative gum chewing
with the potential beneficial effects of nicotine leads to the
hypothesis that nicotine gum chewing can reduce POI and
improve postoperative outcomes (e.g. less morbidity and
shorter length of stay) as well as reduce medical costs [25].
The commercially available and inexpensive nicotine
chewing gum may have a wide clinical application in POI
prevention, by both stimulating the cephalic-vagal reflex and
activating CAIP (Fig. 1). Therefore, we performed a multicen-
ter, randomised, double-blind, controlled pilot study, compar-
ing perioperative use of nicotine chewing gum with normal
chewing gum, to assess the clinical efficacy and safety in
patients undergoing colorectal surgery.
Methods
Study design and participants
This is a prospective, parallel-group, double-blind,
randomised, controlled pilot study, conducted in the
Havenziekenhuis, Rotterdam and the Sint Franciscus
Gasthuis, Rotterdam. Adult patients who underwent an elec-
tive oncologic colorectal resection and gave written consent
were included. Exclusion criteria were severe chronic cardio-
vascular disease or acute cardiovascular disease, severe liver-
or kidney disease, oral or pharyngeal infection, esophagitis,
hypersensitivity to any component of the nicotine gum, previ-
ous colorectal surgery, pregnancy, breast feeding, having an
elevated risk of choking or being unable to chew gum for any
reason.
Study procedures
Patients received either normal chewing gum or Nicorette® 2-
mg chewing gum (2 mg/gum). This nicotine chewing gum is
normally used as nicotine replacement therapy to help control
craving for cigarettes and contains a low dose of nicotine.
Patients had to chew the allocated chewing gum 2 h preoper-
atively and three times a day postoperatively, for half an hour
at a time, until the first passage of faeces and tolerance of solid
food for more than 24 h.
Patients were asked to fill out a questionnaire before sur-
gery and daily after surgery, until postoperative day (POD) 6.
This patient diary contained questions regarding chewing gum
use, oral intake, bowel movements, defaecation, gastrointesti-
nal symptoms and visual analogue scale (VAS) pain score.
Surgeons or surgical residents were asked to fill out case
record forms (CRF) with information regarding both patient
and surgical characteristics, such as age, gender, body mass
index (BMI), American Society of Anesthesiologists (ASA)
score, medication use, smoking, operative procedure, postop-
erative course and postoperative complications (e.g. anasto-
motic leakage (AL), surgical site infection (SSI), fascial de-
hiscence, urinary tract infection (UTI) and pneumonia).
Blood sample analysis
Peripheral blood samples was drawn from patients prior to the
surgical procedure, and in the morning on POD1 and POD3.
Fig. 1 Simplified scheme of hypothesised effect mechanism of nicotine
chewing gum
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Measurements of plasma white blood cell count (WBC) and C-
reactive protein (CRP) were performed by the hospital’s labora-
tory at these same time points. Blood samples were centrifuged
and plasma was stored at −80 °C. Enzyme-linked immunosor-
bent assays (ELISAs) were performed according to instructions
of themanufacturer (PeproTech Inc., RockyHill, USA) to quan-
tify the concentration of the systemic inflammatory marker
interleukin-6 (IL-6). A ratio of samples was calculated, through
dividing the values of POD3 samples by those of the preopera-
tive samples (ratio ¼ cytokine level on POD3cytokine level before surgery ).
Outcome parameters
The primary study parameter was the time from surgery until
the resolution of POI, defined as passage of faeces and toler-
ation of solid food for at least 24 h [26]. Secondary endpoints
included time to first flatus, hospitalisation length, postopera-
tive (infectious) complications, postoperative mortality, post-
operative opioid use, patient reported outcomes (e.g. pain
score, nausea, regurgitations, vomiting, chewing gum use),
inflammatory parameters (e.g. CRP, WBC and IL-6), blood
pressure, body temperature and heart rate.
PPOI was defined as POI that was not resolved after POD5
or recurrent POI after an apparent resolution of POI.
Diagnosis of PPOI was not made directly by the participating
surgeons, but via retrospective review of the patient diary and
medical record, to ensure objectiveness of the primary
endpoint.
Sample size calculation
According to Asao’s gum chewing experiment [24] and
Flood’s nicotine trial [16], a sample size calculation wasmade,
based on a mean POI time of 4.0 days in the chewing gum
groups and an assumption of 2.6 days in the nicotine chewing
gum group with a standard deviation of 1.5 days in both
groups. In order to obtain a power of 80%, with an α level
of 0.05, a number of 16 patients were needed in each group.
As a dropout rate of 20% was expected, a total number of 40
patients (20 patients per group) were needed.
Patient allocation
Randomisation was done with Microsoft Excel 2010
(Microsoft Corporation, Redmond, WA, USA) and results
were placed and concealed in sequentially numbered, sealed,
opaque envelopes by a person who was not connected to the
trial. Patients were asked to participate by surgeons or
specialised nurses who were involved in the trial. Patients
were preoperatively randomised in a 1:1 design to either treat-
ment with normal chewing gum or nicotine chewing gum. The
allocated treatment was given to the patients by the nursing
staff. Both patients and investigators were blinded for treat-
ment allocation.
Statistical analysis
Only patients who completed the full study period were
analysed. Data analysis was carried out using the Statistical
Package for the Social Sciences (SPSS Inc., Chicago, USA,
version 21.0 forWindows). Demographic data were presented
in n (%) and median (interquartile range [IQR]). Categorical
variables were compared using the Fisher’s exact test.
Continuous variables were compared using the Mann-
Whitney U test.
Results
In Fig. 2, the CONSORT flow diagram of the study is shown.
Between January 29, 2015 and July 14, 2016, 62 patients were
assessed for eligibility. Of these patients, 53 were randomly
assigned to the normal chewing gum group or the nicotine
chewing gum group. Two patients in each group withdrew
from participation, because of disliking the chewing gum.
One patient in the normal gum group was unable to continue
treatment protocol, because of postoperative complications
and ICU admission. The other patients withdrew for other
reasons than disliking or being unable to chew the allocated
gum. In total, 40 patients were included for data analysis.
Baseline patient and surgical characteristics were distribut-
ed evenly between both groups, without significant differ-
ences (Table 1). Urinary catheterisation failed in one patient
in the normal gum group and one patient in the nicotine gum
group required vasopressors for hemodynamic support during
surgery. All patients who were admitted to the intensive care
unit (ICU) directly after surgery were transferred to the surgi-
cal ward after 1 day.
The time to primary endpoint (as defined earlier) as well as
the time to first passage of faeces and flatus and length of stay
(LOS) are given in Table 2. No statistically significant differ-
ences were found between groups. In both groups, six patients
(30%) suffered from PPOI on or after POD6. Furthermore,
there was no significant difference in the percentage of reso-
lution of POI on POD1 to 5 (Table 3 and Online Resource Fig.
S1). In a subgroup analysis in which all four open procedures
were excluded, the time to primary endpoint in the nicotine
gum group was shorter, but also not significantly different
from the normal gum group (3.00 days [3.00–4.50] vs. 4.50
[3.00–7.25], p = 0.249).
Six patients in the normal gum group and six in the nicotine
group required a nasogastric tube during their postoperative
stay. Three patients in the normal gum group and four in the
nicotine gum group required total parental nutrition (TPN).
Postoperative complications, reinterventions, readmissions
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and mortality during the first 30 days after surgery are given in
Table 4. No differences were found between both treatment
groups. Only one patient in the nicotine gum group had a short
period of atrial fibrillation and overall, no myocardial infarc-
tion was seen. One patient in each treatment group required
blood transfusion. One patient was readmitted because of
anastomotic leakage and drainage of an intra-abdominal ab-
scess, one patient was readmitted for adhesion ileus and one
for observation of fever of unknown origin. One patient died
during primary hospital stay, due to severe small bowel ische-
mia, caused by venousmesenteric thrombosis. Subgroup anal-
ysis for cases without intra-abdominal infectious complica-
tions during primary stay showed a time to primary endpoint
of 4.00 days (3.00–5.50) vs. 4.50 (4.00–6.00) (p = 0.339) and
LOS of 5.00 days (4.00–8.00) vs. 4.50 (4.00–6.00)
(p = 0.673), for the normal gum and nicotine gum groups,
respectively.
Postoperative opioid use
Fourteen patients in the normal gum group used oral opioids
postoperatively, compared to 11 in the nicotine gum group
(p = 0.514). Respectively, epidural opioids were used in 16
and 14 patients and a combination of oral and epidural opioids
was used in 12 and 9 patients (p = 0.527). One patient in the
normal group used a PCA pump and five patients in the nic-
otine gum group (p = 0.091). Patients in the nicotine gum
group used epidural opioids for a significantly longer time
(3.00 days [2.00–4.25] vs. 2.00 [1.00–.00], p = 0.006), but
duration of oral opioid use did not differ between groups
(1.00 day [0–3.50] vs. 1.00 [0–3.00], p = 0.740).
Patient reported outcomes
Fifteen patients who received normal gum filled out their di-
ary, as compared to 16 patients who received nicotine chewing
gum (p = 1.000). Pain scores (VAS) were significantly lower
in the nicotine gum group on POD3 (1.40 [0.50-] vs. 2.70
[1.50-], p = 0.007), but did not differ on the other postopera-
tive days (Online Resource Fig. S2). No differences were
found in patient reported nausea, vomiting, regurgitations, ab-
dominal distension and appetite (Online Resource Fig. S3).
Treatment compliance, as based on patient reported chewing
gum use, is given in Online Resource Table S1.
Fig. 2 CONSORT flow diagram
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Inflammatory parameters
No significant differences were observed in IL-6 levels and
white blood cell counts in preoperative samples and POD1
and three samples (Online Resource Fig. S4). CRP levels dif-
fered on POD1 in the normal and nicotine gum groups, re-
spectively (71.50mg/L [35.00–92.75] vs. 94.50 mg/L [58.50–
128.25], p = 0.017), but no differences were found in
Table 1 Baseline patient and
surgical characteristics in
treatment groups
Normal gum (n = 20) Nicotine gum (n = 20)
Patient characteristics
Sex
Male 13 (65) 14 (70)
Female 7 (35) 6 (30)
Age (years) 67.50 [60.75–74.75] 69.00 [62.50–70.00]
BMI (kg/m2) 26.91 [23.77–31.61] 25.02 [23.15–27.67]
Smoking 2 (10) 4 (20)
Diabetes mellitus 1 (5) 4 (20)
COPD 2 (10) 3 (15)
Cardiovascular disease 9 (45) 5 (25)
Corticosteroid use 3 (15) 1 (5)
Statin use 4 (20) 5 (25)
Neoadjuvant radiotherapy 1 (5) 0
Neoadjuvant chemoradiotherapy 1 (5) 0
Previous abdominal surgery 3 (15) 3 (15)
ASA classification
ASA I 4 (20) 3 (15)
ASA II 13 (65) 14 (70)
ASA III 3 (15) 2 (10)
ASA IV 0 0
Surgical characteristics
Type of procedure
Low anterior resection 3 (15) 3 (15)
Left hemicolectomy 3 (15) 2 (10)
Right hemicolectomy 8 (40) 6 (30)
Sigmoidectomy 5 (25) 6 (30)
Subtotal colectomy 1 (5) 0
Transverse colon resection 0 3 (15)
Laparoscopic approach 20 (100) 16 (80)
Anastomotic technique
End-to-end 4 (20) 2 (10)
End-to-side 1 (5) 1 (5)
Side-to-end 5 (25) 5 (25)
Side-to-side 10 (50) 11 (55)
Anastomotic configuration
Stapled 12 (60) 13 (65)
Sutured 8 (40) 8 (40)
Protective ileostomy 2 (10) 2 (10)
Nasogastric tube 12 (60) 13 (65)
Intraoperative complications 1 (5) 1 (5)
>50-mL blood loss 5 (25) 9 (45)
Duration of surgery (min) 133 [101–176] 117 [109–150]
Postoperative ICU admission 1 (5) 2 (10)
Data are median [IQR] or n (%)
BMI body mass index, ASA American Society of Anesthesiologists classification, ICU intensive care unit
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preoperative and POD3 samples (Online resource Fig. S4b).
None of the calculated ratios showed differences between both
groups (Table 5). On none of the postoperative days, a statis-
tically significant difference was found in systolic and diastol-
ic blood pressure, and heart rate (Online Resource Fig. S5).
Discussion
This study was the first to investigate the role of nicotine
chewing gum for the prevention of postoperative ileus by
assessing its clinical efficacy and safety in patients undergoing
elective colorectal surgery. By performing this parallel-group,
double-blind, randomised, controlled pilot study, it was not
possible to prove the beneficial effect of nicotine chewing
gum, as compared to normal chewing gum. We hypothesised
that the combination of perioperative gum chewing, with the
potential beneficial effects of nicotine, could improve the res-
olution of POI, but although the median time to primary end-
point seemed shorter in the nicotine gum group (3.50 days vs.
4.50), the difference was not statistically significant.
Moreover, an equal number of patients (n = 6) in each group
suffered from PPOI and LOS did not differ significantly be-
tween both groups. Open procedures are known to worsen
POI outcomes in colorectal surgery as compared to the lapa-
roscopic approach [27]. Since all four open procedures in this
study were in the nicotine gum group, a subgroup analysis
was performed in which these four procedures were excluded.
This showed an improvement in median time to primary end-
point (3.50 vs. 3.00 days) and length of stay (4.50 vs.
4.00 days) in the nicotine gum group, but although these open
procedures influenced the outcomes, they did not provide a
complete explanation for the lack of efficacy, since a signifi-
cant difference between both groups was still not found.
A limitation of this study might be the relatively small
sample size of 40 patients in total. However, our sample size
calculation was based on the results of Asao et al. [24] who
showed significant effects of chewing gum in a total of 19
patients. With a larger sample size than we initially calculated,
we might have had more power to make a better
distinguishment between the effects of sham feeding with nor-
mal chewing gum and the hypothesised additional effects of
sham feeding with nicotine chewing gum.
Experimental studies have shown that a specific α7-
nAChR agonist (AR-R17779) ameliorates POI in rats and that
stimulation of the α7-nAChR improves survival of sepsis in
rats [11, 28]. Nevertheless, as clinical results of nicotine use
for POI after colorectal surgery were still lacking, the second
aim of this pilot study was to evaluate the safety of nicotine
chewing gum for the purpose of preventing POI. Because of
concerns of systemic effects induced by nicotine administra-
tion, particularly cardiovascular complications [29], we decid-
ed to use Nicorette® 2 mg. This relatively low dose might
have potentially been another reason for the lack of efficacy
of the nicotine chewing gum in this study. However, the use of
Nicorette® 2 mg in a perioperative setting of elective colorec-
tal surgery, which has not been described in the literature
before, seems to be safe.
No myocardial infarctions were registered in this study and
only one patient had one short period of atrial fibrillation. This
patient did receive nicotine chewing gum, but was known to
have had previous episodes of paroxysmal atrial fibrillation.
These findings are consistent with a previously published
Cochrane Review, concluding that there is no evidence that
Table 3 Resolution of POI
Normal gum (n = 20) Nicotine gum (n = 20) p value
Resolution of POI
POD1 0 0 –
POD2 0 2 (10) 0.487
POD3 6 (30) 9 (45) 0.515
POD4 11 (55) 13 (65) 0.748
POD5 14 (70) 14 (70) 1.000
POD6 or later 20 (100) 20 (100) 1.000
Data are n (%)
Table 2 Time to primary
endpoint, time to first passage of
faeces and flatus, length of stay in
days
Normal gum (n = 20) Nicotine gum (n = 20) p value
Time to primary endpoint (days) 4.50 [3.00–7.25] 3.50 [3.00–4.25] 0.398
Time to first passage of faeces (days) 3.00 [1.75–5.00] 3.00 [1.75–4.00] 0.414
Time to first passage of flatus (days) 1.00 [1.00–2.25] 1.00 [1.00–1.00] 0.454
Length of stay (days) 5.50 [4.00–8.50] 4.50 [4.00–6.00] 0.738
Data are median [IQR]
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nicotine replacement therapy increases the risk of heart attacks
[30]. Moreover, apart from cardiovascular complications, no
differences were found inmajor andminor postoperative com-
plications, reinterventions, readmissions and mortality be-
tween the normal and nicotine chewing gum groups.
Overall, only one patient—enrolled in the nicotine chewing
gum group—died during primary hospital stay on the 15th
postoperative day. We did not consider usage of the nicotine
chewing gum related to the cause of death, which was a result
of intestinal ischemia caused by venous mesenteric
thrombosis.
To combine the potential benefits of sham feeding with
chewing gum and nicotine, we chose to use nicotine chewing
gum in this pilot study. The reason being that this facilitated
the possibility for a simple blinded comparison with normal
chewing gum. However, a limitation of nicotine administra-
tion through chewing gum is that a sufficient release of nico-
tine is dependent on treatment compliance of the patient. All
patients in this study were asked to report their use of chewing
gum in the patient diary and it can be concluded that compli-
ance to chewing the allocated gum is decreasing in the first
three postoperative days. Conceivably, a more constant way of
nicotine administration, such as the nicotine patches which
Habib et al. [15] used in their study, might have given a more
continuous release of nicotine.
If indeed the effective dose of nicotine would be too low in
some patients, either due to low administered dose, insufficient
exposure to the nicotine chewing gum or both, this might ac-
count for the absence of significant differences between the
measured clinical and inflammatory parameters in both groups.
Table 5 Inflammatory
parameters (Interleukin-6 (IL-6),
C-reactive protein (CRP) and
white blood cell (WBC) count
Normal gum (n = 20) Nicotine gum (n = 20) p value
IL-6 (pg/mL)
Preoperative 1088.95 [529.65–1680.70] 1108.40 [547.18–1732.38] 0.663
POD1 881.80 [516.90–2138.70] 1047.65 [752.53–1930.10] 0.883
POD3 959.00 [648.90–2043.60] 987.40 [518.38–2139.75] 0.940
Ratio 1.13 [0.99–1.54] 1.12 [0.89–1.24] 0.517
CRP (mg/L)
Preoperative 2.60 [1.00–4.75] 3.70 [2.25–23.38] 0.089
POD1 71.50 [35.00–92.75] 94.50 [58.50–128.25] 0.017
POD3 99.50 [76.25–179.50] 151.00 [101.75–188.50] 0.180
Ratio 45.83 [19.70–83.68] 33.92 [6.59–79.10] 0.180
WBC count (×109/L)
Preoperative 7.10 [3.90–9.60] 6.60 [6.25–9.10] 0.477
POD1 12.30 [7.65–15.45] 12.30 [10.85–13.85] 0.865
POD3 8.50 [4.95–10.60] 9.00 [7.15–11.85] 0.583
Ratio 1.08 [0.95–1.59] 1.15 [0.99–1.77] 0.734






Normal gum (n = 20) Nicotine gum (n = 20) p value
Atrial fibrillation 0 1 (5) 1.000
Fascial dehiscence 0 0 –
Colorectal anastomotic leakage 2 (10) 0 0.487
Intra-abdominal abscess 1 (5) 0 1.000
Myocardial infarction 0 0 –
Pneumonia 1 (5) 0 1.000
Surgical site infection 4 (20) 2 (10) 0.661
Urinary retention 0 1 (5) 1.000
Urinary tract infection 2 (10) 1 (5) 1.000
Reinterventions (<30 days) 4 (20) 2 (10) 0.661
Readmissions (<30 days) 3 (15) 0 0.231
Mortality (<30 days) 0 1 (5) 1.000
Data are n (%)
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Il-6 and CRP levels, as well as WBC, were analysed in
venous blood samples, as markers of the immune response,
because it was hypothesised that this response would be less
pronounced in patients in the nicotine chewing gum group.
Overall lower levels of any of the three inflammatory param-
eters (IL-6, CRP andWBC)were not seen in this group and no
differences were found, when compared to the normal
chewing gum group, except for a significant difference of
CRP levels on POD1. Sparreboom et al. [31] have concluded
in their meta-analysis that levels of pro-inflammatory cyto-
kines, such as IL-6, were higher in peritoneal samples as com-
pared to serum samples after colorectal surgery, which might
also explain why significant changes and differences were not
detected in our serum samples. Moreover, postoperative infec-
tious complications, such as surgical site infections and pneu-
monia, could have affected the levels of these inflammatory
parameters in both groups.
No differences in patient reported outcomes, such as nau-
sea, vomiting, regurgitations, abdominal distension and appe-
tite, were found. However, patient reported pain scores were
significantly lower in the nicotine gum group as compared to
the normal gum group on POD3 (1.40 [0.50-] vs. 2.70 [1.50-],
p = 0.007). Although promising, this difference could partially
be explained by the fact that patients in this group received
epidural opioids for a significantly longer period of time
(3.00 days [2.00–4.25] vs. 2.00 [1.00–.00], p = 0.006).
However, the exact reason for a longer use of epidural opioids
remains uncertain, since the decision to stop epidural anaes-
thesia in this study was made by the anaesthesiologist, who
was blinded for patient allocation, with the aim to stop as early
as possible, and preferably on or before POD2–3. These de-
cisions were not registered prospectively. Furthermore, no
significant differences in patient outcomes were found be-
tween both groups which might explain the extended require-
ment for epidural opioids in the nicotine gum group.
In conclusion, this study is the first to evaluate the potential
beneficial role of nicotine chewing gum for another purpose
than NRT in a randomised and double-blind clinical setting.
Although the hypothesised potential benefits of nicotine
chewing gum, as a cheap and readily available treatment op-
tion, seemed promising, no evident beneficial effects were
found. This might be attributed to the sample size, the dose
of the nicotine chewing gum and insufficient patient compli-
ance to the allocated chewing gum. People in the nicotine
chewing gum group seemed to experience less pain in the first
three postoperative days, but a difference could only be prov-
en on POD3. Therefore, more data on the effects of nicotine
gum on bowel recovery after surgery are awaited [32].
Furthermore, this study provides positive new insights on
the safety of nicotine chewing in the setting of patients under-
going elective colorectal surgery. Future research should focus
on other means of nicotine administration to patients under-
going colorectal surgery (e.g. patches), whether or not
combined with normal chewing gum, and in higher doses, to
further assess its effects on gastrointestinal recovery after co-
lorectal surgery.
Acknowledgements We thank all patients for their participation in this
study, and all involved staff members for their efforts, in particular, A. de
Boer, I. Sendar, A. van der Spek, W. Lee and A. van Duuren. This pilot
study was funded by Stichting Coolsingel (Rotterdam, The Netherlands).
Compliance with ethical standards In accordance with the Dutch law
on medical research in humans, this study was approved by the
Institutional Review Board of the Erasmus University Medical Center,
Rotterdam, The Netherlands and the Institutional Review Boards of both
participating hospitals. Patients gave their written consent after receiving
oral and written information. This study was investigator initiated. All
procedures performed in studies involving human participants were in
accordance with the ethical standards of the institutional research com-
mittee and with the 1964 Helsinki declaration and its later amendments or
comparable ethical standards.
Source of funding Stichting Coolsingel, Schiekade 75, 3033 BD,
Rotterdam, The Netherlands, E-mail: secretariaat@stichtingcoolsingel.nl.
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Lubbers T, BuurmanW, Luyer M (2010) Controlling postoperative
ileus by vagal activation. World J Gastroenterol 16(14):1683–1687
2. Gero D, Gié O, Hübner M, Demartines N, Hahnloser D (2016)
Postoperative ileus: in search of an international consensus on def-
inition, diagnosis, and treatment. Langenbeck’s Arch Surg 402:
149–158:1–10. doi:10.1007/s00423-016-1485-1
3. Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W,
Wallin BA, Alvimopan Postoperative Ileus Study G (2004)
Alvimopan, a novel, peripherally acting mu opioid antagonist: re-
sults of a multicenter, randomized, double-blind, placebo-con-
trolled, phase III trial of major abdominal surgery and postoperative
ileus. Ann Surg 240(4):728–734 discussion 734-725
4. Artinyan A, Nunoo-Mensah JW, Balasubramaniam S, Gauderman
J, Essani R, Gonzalez-Ruiz C, Kaiser AM, Beart RW Jr (2008)
Prolonged postoperative ileus-definition, risk factors, and predic-
tors after surgery. World J Surg 32(7):1495–1500
5. Schuster R, Grewal N, Greaney GC, Waxman K (2006) Gum
chewing reduces ileus after elective open sigmoid colectomy.
Arch Surg 141(2):174–176
6. Luckey A, Livingston E, Tache Y (2003) Mechanisms and treat-
ment of postoperative ileus. Arch Surg 138(2):206–214
7. Bauer AJ, Boeckxstaens GE (2004) Mechanisms of postoperative
ileus. Neurogastroenterol Motil 16(Suppl 2):54–60
8. Boeckxstaens GE, de JongeWJ (2009) Neuroimmune mechanisms
in postoperative ileus. Gut 58(9):1300–1311
9. Kalff JC, Schraut WH, Simmons RL, Bauer AJ (1998) Surgical
manipulation of the gut elicits an intestinal muscularis
1274 Int J Colorectal Dis (2017) 32:1267–1275
inflammatory response resulting in postsurgical ileus. Ann Surg
228(5):652–663
10. Turler A, Moore BA, Pezzone MA, Overhaus M, Kalff JC, Bauer
AJ (2002) Colonic postoperative inflammatory ileus in the rat. Ann
Surg 236(1):56–66
11. The FO, Boeckxstaens GE, Snoek SA, Cash JL, Bennink R, Larosa
GJ, van den Wijngaard RM, Greaves DR, de Jonge WJ (2007)
Activation of the cholinergic anti-inflammatory pathway amelio-
rates postoperative ileus in mice. Gastroenterology 133(4):1219–
1228
12. van der Zanden EP, Snoek SA, Heinsbroek SE, Stanisor OI,
Verseijden C, Boeckxstaens GE, Peppelenbosch MP, Greaves DR,
Gordon S, De Jonge WJ (2009) Vagus nerve activity augments intes-
tinal macrophage phagocytosis via nicotinic acetylcholine receptor
alpha4beta2. Gastroenterology 137(3):1029–1039 1039 e1021-1024
13. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li
JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ
(2003) Nicotinic acetylcholine receptor alpha7 subunit is an essen-
tial regulator of inflammation. Nature 421(6921):384–388
14. Damaj MI, Meyer EM, Martin BR (2000) The antinociceptive ef-
fects of alpha7 nicotinic agonists in an acute pain model.
Neuropharmacology 39(13):2785–2791
15. Habib AS, White WD, El Gasim MA, Saleh G, Polascik TJ, Moul
JW, Gan TJ (2008) Transdermal nicotine for analgesia after radical
retropubic prostatectomy. Anesth Analg 107(3):999–1004
16. Flood P, Daniel D (2004) Intranasal nicotine for postoperative pain
treatment. Anesthesiology 101(6):1417–1421
17. Behm B, Stollman N (2003) Postoperative ileus: etiologies and
interventions. Clin Gastroenterol Hepatol 1(2):71–80
18. Vasquez W, Hernandez AV, Garcia-Sabrido JL (2009) Is gum
chewing useful for ileus after elective colorectal surgery? A sys-
tematic review and meta-analysis of randomized clinical trials. J
Gastrointest Surg 13(4):649–656
19. Chan MK, Law WL (2007) Use of chewing gum in reducing post-
operative ileus after elective colorectal resection: a systematic re-
view. Dis Colon Rectum 50(12):2149–2157
20. Purkayastha S, TilneyHS, Darzi AW, Tekkis PP (2008)Meta-analysis
of randomized studies evaluating chewing gum to enhance postoper-
ative recovery following colectomy. Arch Surg 143(8):788–793
21. Li S, Liu Y, Peng Q, Xie L, Wang J, Qin X (2013) Chewing gum
reduces postoperative ileus following abdominal surgery: a meta-
analysis of 17 randomized controlled trials. J Gastroenterol Hepatol
28(7):1122–1132
22. Noble EJ, Harris R, Hosie KB, Thomas S, Lewis SJ (2009) Gum
chewing reduces postoperative ileus? A systematic review and me-
ta-analysis. Int J Surg 7(2):100–105
23. Short V, Herbert G, Perry R, Atkinson C, Ness AR, Penfold C,
Thomas S, Andersen HK, Lewis SJ (2015) Chewing gum for post-
operative recovery of gastrointestinal function. Cochrane Database
Syst Rev 2:CD006506
24. Asao T, Kuwano H, Nakamura J, Morinaga N, Hirayama I, Ide M
(2002) Gum chewing enhances early recovery from postoperative
ileus after laparoscopic colectomy. J Am Coll Surg 195(1):30–32
25. Wu Z, Boersema GS, Jeekel J, Lange JF (2014) Nicotine gum
chewing: a novel strategy to shorten duration of postoperative ileus
via vagus nerve activation. Med Hypotheses 83(3):352–354
26. van Bree SH, Bemelman WA, Hollmann MW, Zwinderman AH,
Matteoli G, El Temna S, The FO, Vlug MS, Bennink RJ,
Boeckxstaens GE (2014) Identification of clinical outcome mea-
sures for recovery of gastrointestinal motility in postoperative ileus.
Ann Surg 259(4):708–714
27. Holte K, Kehlet H (2000) Postoperative ileus: a preventable event.
Br J Surg 87(11):1480–1493. doi:10.1046/j.1365-2168.2000.
01595.x
28. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed
Y, Wang H, Metz C, Miller EJ, Tracey KJ, Ulloa L (2004)
Cholinergic agonists inhibit HMGB1 release and improve survival
in experimental sepsis. Nat Med 10(11):1216–1221
29. Thomas GA, Rhodes J, Mani V, Williams GT, Newcombe RG,
Russell MA, Feyerabend C (1995) Transdermal nicotine as main-
tenance therapy for ulcerative colitis. N Engl J Med 332(15):988–
992
30. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill
K, Lancaster T (2012) Nicotine replacement therapy for smoking
cessation. Cochrane Database Syst Rev 11:CD000146
31. Sparreboom CL, Wu Z, Dereci A, Boersema GS, Menon AG, Ji J,
Kleinrensink GJ, Lange JF (2016) Cytokines as early markers of
colorectal anastomotic leakage: a systematic review and meta-anal-
ysis. Gastroenterol Res Pract 2016:3786418
32. Weiss E Cleveland clinic florida does nicotine gum enhance bowel
recovery after colorectal surgery? In: In: ClinicalTrials.gov
[Internet]. Bethesda (MD): National Library of Medicine (US).
2000- [cited 2016 Dec 30] Available from: https://clinicaltrials.
gov/ct2/show/NCT01662115 NLM Identifier: NCT01662115
Int J Colorectal Dis (2017) 32:1267–1275 1275
